國藥控股(01099.HK)附屬與海泰新光合作 深化醫療器械產業佈局
國藥控股(01099.HK)宣佈旗下重大附屬公司中國醫療器械於12月6日與青島海泰新光科技股份簽訂《合資合作備忘錄》,擬與其設立合資公司,旨在以醫用內窺鏡整機系統爲切入點,共同開發中國醫用內窺鏡市場,將合資公司打造成爲國產醫用內窺鏡整機和微創外科領域的領先企業。
作爲國藥控股旗下專業從事醫療器械業務板塊的主力軍,國藥器械以「讓更多的民衆享受更好的健康服務」爲使命,立足「責任央企、行業領袖」的品牌定位,主要從事醫療器械的研發、製造、流通、服務等領域,經營網絡覆蓋全國。公司近年來發展迅速,年營業收入超過500億元人民幣,持續提升完善自身在供應鏈與物流體系建設領域的業務能力及服務質量,已經成爲國內領先的全產業鏈醫療器械綜合服務運營商,並不斷引領行業健康轉型發展。
海泰新光是國內醫用成像器械行業的領先創新企業,專業從事醫用內窺鏡器械和光學產品的研發、生產和銷售,並於2021年2月26日成功登陸境內科創板。此次與海泰新光簽訂《合資合作備忘錄》,確定了雙方的合作共識。根據中國醫療器械行業協會統計,中國內窺鏡市場年均增長率將保持在20%左右,行業增長潛力巨大。此次合作有望爲國藥控股的業務擴展注入新鮮血液,爲合資公司長期打開成長空間。
根據備忘錄,國藥器械及海泰新光擬以現金出資方式按51:49的比例設立合資公司,合資公司註冊資本總額爲1.6億人民幣。公司將以中國醫用內窺鏡市場爲瞄準點,建立自主品牌,迅速實現取證和銷售,由此逐步提升其在中國市場的市場佔有率。與此同時,合資公司還將同步啓動包括3D、人工智能以及其他微創外科技術和產品的研發和迭代,力圖打造國產醫用內窺鏡整機和微創外科領域領先企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.